Comparative effects of two once-daily regimens of policosanol in patients with type II hypercholesterolemia

Current Therapeutic Research - Clinical and Experimental

Volumn 58, Issue 3, 1997, Pages 154-162

  Castaño, Gladys ^a   Más, Rosa ^a   Fernández, Julio César ^a   Illnait, José ^a  

^a NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

Author keywords

cholesterol lowering drug; dyslipidemia; lipid lowering drug; policosanol; type II hypercholesterolemia

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; POLICOSANOL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD CHEMISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPOPROTEINEMIA TYPE 2; MAJOR CLINICAL STUDY; MALE; MEAL; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; TABLET;

EID: 0030889985     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(97)80010-0     Document Type: Article

References (32)

1. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I: Reduction in incidence of coronary heart disease. JAMA. 1984;251: 351-364.
2. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. II: The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251:365-374.
3. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. NEJM. 1987;317:1237-1245.
4. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol-lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4 S). Lancet. 1994;344:1383-1389.
5. Sheperd J, Cobbe SM, Christopher G, et al, for the West of Scotland Coronary Prevention Study Group: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. NEJM. 1995;333:1301-1307.
6. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015-3023.
7. Pyorala K, De Backer G, Graham I, et al, on behalf of the Task Force. Prevention of coronary heart disease in clinical practice: Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Published simultaneously in Eur Heart J. 1994;15:1300-1331 and Atherosclerosis. 1994;110:121-161.
8. Pyorala K, De Backer G, Graham I, et al, on behalf of the Task Force. Prevention of coronary heart disease in clinical practice: Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Published simultaneously in Eur Heart J. 1994;15:1300-1331 and Atherosclerosis. 1994;110:121-161.
9. Arruzazabala M de L, Carbajal D, Más R, et al. Cholesterol-lowering of policosanol in rabbits. Biol Res. 1994;27:205-208.
10. Rodríguez C, Mesa R, Más R, et al. Estudio del efecto sobre lípidos y lipoproteínas séricos y de la tolerancia al tratamiento oral con dosis crecientes de policosanol en monos (Macaca arctoides). Arch Venezol Farmacol Terap. 1992;11:74-79.
11. Hernández F, Illnait J, Más R, et al. Effects of policosanol on serum lipids and lipoproteins in healthy volunteers. Curr Ther Res. 1992;51:568-575.
12. Castaño G, Zardoya R, Illnait J, et al. Efectos del tratamiento con Ateromixol (PPG) (5 mg) en pacientes con hiperlipoproteinemia tipo II. PCM. 1991;5:21-28.
13. Soltero I, Fuenmayor I, Colmenares J. Estudio comparative doble ciego de la eficacia y tolerancia del policosanol bezafibrato en pacientes con hiperlipidemias tipo II. Arch Venezol Farmacol Terap. 1993;12:71-76.
14. Pons P, Rodríguez M, Robaina C, et al. Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolemia and tolerability to treatment. Int J Clin Pharmacol Res. 1994;14:27-33.
15. Pons P, Rodríguez M, Más R, et al. One year efficacy and safety of policosanol in patients with type II hypercholesterolemia. Curr Ther Res. 1994;55:1084-1092.
16. Aneiros E, Más R, Calderón B, et al. Effect of policosanol in lowering cholesterol levels in patients with type II hypercholesterolemia. Curr Ther Res. 1995;56:176-182.
17. Canetti M, Moreira M, Illnait J, et al. One year study on the effect of policosanol (5 mg-twice-a-day) on lipid profile in patients with type II hypercholesterolemia. Adv Ther. 1995;12:245-254.
18. Canetti M, Moreira M, Illnait J, et al. A two year study on the efficacy and tolerability of policosanol in patients with type II hyperlipoproteinemia. Int J Clin Pharmacol Res. 1995;15:159-165.
19. Castaño G, Tula L, Canetti Morera M, et al. Effect of policosanol (10 mg/day) in hypertensive patients with primary hypercholesterolemia. Curr Ther Res. 1996;57:691-699.
20. Zardoya R, Tula L, Castaño G, et al. Effects of policosanol on hypercholesterolemic patients with abnormal serum biochemical indicators of hepatic function. Curr Ther Res. 1996;57:568-577.
21. Torres O, Agramonte AJ, Illnait J, et al. Treatment of hypercholesterolemia in NIDDM with policosanol. Diabetes Care. 1995;18:393-397.
22. Menéndez R, Fernández I, Del Río A, et al. Policosanol inhibits cholesterol biosynthesis and enhances LDL processing in cultured human fibroblasts. Biol Res. 1994;27:199-203.
23. Menéndez R, Amor AM, González RM, et al. Effect of policosanol on the hepatic cholesterol biosynthesis of normocholesterolemic rats. Biol Res. 1996;29:253-257.
24. Menéndez R, Arruzazabala ML, Más R, et al. Cholesterol-lowering effect of policosanol on rabbits with hypercholesterolemia induced by a wheat starch-casein in diet. Br J Nutr. In press.
25. Alemán C, Más R, Hernández C, et al. A 12 month study of policosanol oral toxicity in Sprague-Dawley rats. Toxicol Lett. 1994;70:77-87.
26. Mesa AR, Más R, Noa M, et al. Toxicity of policosanol in Beagle dogs: One year study. Toxicol Lett. 1994;73:81-90.
27. Alemán CL, Más R, Noa M, et al. Carcinogenicity of policosanol in Sprague Dawley rats: A 24 month study. Teratog Carcinog Mutag. 1994;14:239-249.
28. Alemán CL, Rodeiro I, Noa M, et al. Acute subchronical and chronic toxicity of policosanol in rats. In: Abstracts of the Sixth International Congress of Toxicology, June 28-July 3, 1994; Rome, Italy, p. 428.
29. Seigler L, Wu WT. Separation of serum high-density lipoprotein for cholesterol determination: Ultracentrifugation vs precipitation with sodium phosphotungstat and magnesium chloride. Clin Chem. 1981;27:838-841.
30. Friedewald WT, Levy RI, Friederickson SD. Estimation of the concentration of low-density-lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
31. O'Brien PC, Shampo MC. Statistical considerations for performing multiple tests in a single experiment. 5. Comparing two therapies with respect to several endpoints. Mayo Clin Proc. 1988;63:1140-1143.
32. Parker TS, McNamara DJ, Brown C. Mevalonic acid in human plasma: Relationship of concentration and circadian rhythm to cholesterol synthesis rates in man. Proc Natl Acad Sci USA. 1982;79:3037-3041.